Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock is trading at $16.83, up 1.75%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TEVA shares have gain 1.51% over the last week, with a monthly amount glided 0.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] stock has seen the most recent analyst activity on June 06, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $24. Previously, Truist started tracking the stock with Buy rating on May 28, 2025, and set its price target to $25. On May 12, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $23 on the stock. Argus upgraded its rating to a Buy but stick to its price target of $20 on July 10, 2024. JP Morgan upgraded its rating to a Neutral but $14 remained the price target by the analyst firm on March 08, 2024. Piper Sandler upgraded its rating to Overweight for this stock on February 12, 2024, and upped its price target to $19. In a note dated January 23, 2024, Jefferies upgraded an Buy rating on this stock and boosted its target price from $10 to $14.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock has fluctuated between $12.47 and $22.80 over the past year. Currently, Wall Street analysts expect the stock to reach $20.71 within the next 12 months. Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] shares were valued at $16.83 at the most recent close of the market. An investor can expect a potential return of 23.05% based on the average TEVA price forecast.
Analyzing the TEVA fundamentals
Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA] reported sales of 16.66B for the trailing twelve months, which represents a growth of 2.43%. Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.21 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.71.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.27 points at the first support level, and at 15.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.31, and for the 2nd resistance point, it is at 17.80.
Ratios To Look Out For
For context, Teva- Pharmaceutical Industries Ltd. ADR’s Current Ratio is 1.06. As well, the Quick Ratio is 0.77, while the Cash Ratio is 0.15. Considering the valuation of this stock, the price to sales ratio is 1.16, the price to book ratio is 3.08.
Transactions by insiders
Recent insider trading involved Kalif Eliyahu Sharon, EVP, Chief Financial Officer, that happened on Jun 12 ’25 when 55775.0 shares were sold. Officer, Kalif Eliyahu Sharon completed a deal on Jun 12 ’25 to buy 55775.0 shares. Meanwhile, EVP, Global Operations Shields Matthew sold 6206.0 shares on Jun 03 ’25.
